Ultragenyx Pharmaceutical (LTS:0LIF) Common Stock : $0.1 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ultragenyx Pharmaceutical Common Stock?

Ultragenyx Pharmaceutical's quarterly common stock increased from Sep. 2023 ($0.1 Mil) to Dec. 2023 ($0.1 Mil) and increased from Dec. 2023 ($0.1 Mil) to Mar. 2024 ($0.1 Mil).

Ultragenyx Pharmaceutical's annual common stock increased from Dec. 2021 ($0.1 Mil) to Dec. 2022 ($0.1 Mil) and increased from Dec. 2022 ($0.1 Mil) to Dec. 2023 ($0.1 Mil).

Ultragenyx Pharmaceutical Common Stock Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Common Stock Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.06

0.07

0.08

Ultragenyx Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.07	0.07	0.07	0.08	0.08

Ultragenyx Pharmaceutical Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ultragenyx Pharmaceutical (LTS:0LIF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (LTS:0LIF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

RARE:USA RARE:Mexico UP0:Germany

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (LTS:0LIF) Headlines

No Headlines